Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
June 13, 2016 16:01 ET | Revance Therapeutics, Inc
NEWARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
June 02, 2016 18:12 ET | Revance Therapeutics, Inc
- Portfolio covers diverse and novel indications, compositions and formulations - - Acquisition expands IP rights into inflammation, pain, dermatologic and neurologic disorders- NEWARK, Calif., June...
Revance to Participate in Upcoming Investor Conferences
May 31, 2016 16:05 ET | Revance Therapeutics, Inc
NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Releases First Quarter 2016 Results
May 09, 2016 16:05 ET | Revance Therapeutics, Inc
- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow’s Feet Lines –- Moves Phase 2 Dose-Escalating Trial for RT002 Injectable for Cervical Dystonia into Second Cohort - ...
Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016
April 25, 2016 16:01 ET | Revance Therapeutics, Inc
NEWARK, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development
March 14, 2016 16:05 ET | Revance Therapeutics, Inc
NEWARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology
March 05, 2016 13:45 ET | Revance Therapeutics, Inc
- Findings confirm statistically significantly greater duration of effect for RT002 compared to BOTOX® Cosmetic - - 40U dose of RT002 planned to enter pivotal Phase 3 study in the second half of 2016...
Revance Releases Fourth Quarter and Full Year 2015 Results
March 02, 2016 16:05 ET | Revance Therapeutics, Inc
- Announces 2016 Outlook -- On Track to Achieve Multiple Clinical Development Milestones in 2016 - NEWARK, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC),...
Revance to Participate in Upcoming Investor Conferences
February 23, 2016 16:05 ET | Revance Therapeutics, Inc
NEWARK, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics to Release Fourth Quarter and Full Year 2015 Financial Results Wednesday, March 2, 2016
February 17, 2016 16:05 ET | Revance Therapeutics, Inc
NEWARK, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...